标题
Ipilimumab in melanoma
作者
关键词
-
出版物
Expert Review of Anticancer Therapy
Volume 16, Issue 8, Pages 811-826
出版商
Informa UK Limited
发表日期
2016-07-13
DOI
10.1080/14737140.2016.1211936
参考文献
相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。- Inflammatory Orbitopathy Associated With Ipilimumab
- (2017) Claire A. Sheldon et al. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
- Ipilimumab-Induced Hypophysitis and Uveitis in a Patient With Metastatic Melanoma and a History of Ipilimumab-Induced Skin Rash
- (2017) Neelima N. Nallapaneni et al. Journal of the National Comprehensive Cancer Network
- Left Ventricular Dysfunction After Treatment With Ipilimumab for Metastatic Melanoma
- (2016) Mary E. Roth et al. AMERICAN JOURNAL OF THERAPEUTICS
- Acute renal allograft rejection after immune checkpoint inhibitor therapy for metastatic melanoma
- (2016) L. Spain et al. ANNALS OF ONCOLOGY
- Baseline neutrophils and derived neutrophil-to-lymphocyte ratio: prognostic relevance in metastatic melanoma patients receiving ipilimumab
- (2016) P. F. Ferrucci et al. ANNALS OF ONCOLOGY
- Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
- (2016) S Bowyer et al. BRITISH JOURNAL OF CANCER
- Baseline Peripheral Blood Biomarkers Associated with Clinical Outcome of Advanced Melanoma Patients Treated with Ipilimumab
- (2016) A. Martens et al. CLINICAL CANCER RESEARCH
- Clinical, Endoscopic, and Histologic Characteristics of Ipilimumab-Associated Colitis
- (2016) Eduard Cornelis Verschuren et al. Clinical Gastroenterology and Hepatology
- Ipilimumab-associated minimal-change disease
- (2016) Jason M. Kidd et al. KIDNEY INTERNATIONAL
- Sequential administration of nivolumab and ipilimumab with a planned switch in patients with advanced melanoma (CheckMate 064): an open-label, randomised, phase 2 trial
- (2016) Jeffrey S Weber et al. LANCET ONCOLOGY
- Ipilimumab in anti-PD1 refractory metastatic melanoma
- (2016) Aurélie Jacobsoone-Ulrich et al. MELANOMA RESEARCH
- Ipilimumab-induced acute generalized exanthematous pustulosis in a patient with metastatic melanoma
- (2016) Shelley J.E. Hwang et al. MELANOMA RESEARCH
- CNS demyelination and enhanced myelin-reactive responses after ipilimumab treatment
- (2016) Yonghao Cao et al. NEUROLOGY
- Immunotherapy-Associated Hemolytic Anemia with Pure Red-Cell Aplasia
- (2016) Ranjit Nair et al. NEW ENGLAND JOURNAL OF MEDICINE
- Late-onset pericardial tamponade, bilateral pleural effusions and recurrent immune monoarthritis induced by ipilimumab use for metastatic melanoma
- (2016) Constantin A Dasanu et al. JOURNAL OF ONCOLOGY PHARMACY PRACTICE
- Ipilimumab Therapy in Patients With Advanced Melanoma and Preexisting Autoimmune Disorders
- (2016) Douglas B. Johnson et al. JAMA Oncology
- New-Onset Mediastinal and Central Nervous System Sarcoidosis in a Patient with Metastatic Melanoma Undergoing CTLA4 Monoclonal Antibody Treatment
- (2016) Kevin P. Murphy et al. Oncology Research and Treatment
- Meningoencephalitis Following Ipilimumab Administration in Metastatic Melanoma
- (2015) Matthew K. Stein et al. AMERICAN JOURNAL OF THE MEDICAL SCIENCES
- Ipilimumab Granulomatous Interstitial Nephritis
- (2015) Bijin Thajudeen et al. AMERICAN JOURNAL OF THERAPEUTICS
- Cutaneous melanoma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
- (2015) R. Dummer et al. ANNALS OF ONCOLOGY
- Management of immune checkpoint blockade dysimmune toxicities: a collaborative position paper
- (2015) S. Champiat et al. ANNALS OF ONCOLOGY
- Baseline neutrophil-to-lymphocyte ratio is associated with outcome of ipilimumab-treated metastatic melanoma patients
- (2015) P F Ferrucci et al. BRITISH JOURNAL OF CANCER
- High neutrophil to lymphocyte ratio measured before starting ipilimumab treatment is associated with reduced overall survival in patients with melanoma
- (2015) J. Zaragoza et al. BRITISH JOURNAL OF DERMATOLOGY
- New-onset uveitis during CTLA-4 blockade therapy with ipilimumab in metastatic melanoma patient
- (2015) Elisabetta Miserocchi et al. CANADIAN JOURNAL OF OPHTHALMOLOGY-JOURNAL CANADIEN D OPHTALMOLOGIE
- Anticancer immunotherapy by CTLA-4 blockade: obligatory contribution of IL-2 receptors and negative prognostic impact of soluble CD25
- (2015) Dalil Hannani et al. CELL RESEARCH
- Myeloid Cells and Related Chronic Inflammatory Factors as Novel Predictive Markers in Melanoma Treatment with Ipilimumab
- (2015) C. Gebhardt et al. CLINICAL CANCER RESEARCH
- Ipilimumab-Induced Adrenalitis
- (2015) Sara Bacanovic et al. CLINICAL NUCLEAR MEDICINE
- Stereotactic Radiosurgery for Melanoma Brain Metastases in Patients Receiving Ipilimumab: Safety Profile and Efficacy of Combined Treatment
- (2015) Ana P. Kiess et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Treatment possibilities of ipilimumab-induced thrombocytopenia--case study and literature review
- (2015) J. Kopecky et al. JAPANESE JOURNAL OF CLINICAL ONCOLOGY
- Myasthenia Gravis Induced by Ipilimumab in Patients With Metastatic Melanoma
- (2015) Douglas B. Johnson et al. JOURNAL OF CLINICAL ONCOLOGY
- Safety of Infusing Ipilimumab Over 30 Minutes
- (2015) Parisa Momtaz et al. JOURNAL OF CLINICAL ONCOLOGY
- Five-Year Survival Rates for Treatment-Naive Patients With Advanced Melanoma Who Received Ipilimumab Plus Dacarbazine in a Phase III Trial
- (2015) Michele Maio et al. JOURNAL OF CLINICAL ONCOLOGY
- Immune-Related Adverse Events, Need for Systemic Immunosuppression, and Effects on Survival and Time to Treatment Failure in Patients With Melanoma Treated With Ipilimumab at Memorial Sloan Kettering Cancer Center
- (2015) Troy Z. Horvat et al. JOURNAL OF CLINICAL ONCOLOGY
- Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma
- (2015) Dirk Schadendorf et al. JOURNAL OF CLINICAL ONCOLOGY
- Vogt-Koyanagi-Harada-like Syndrome After CTLA-4 Inhibition With Ipilimumab for Metastatic Melanoma
- (2015) Jason N. Crosson et al. JOURNAL OF IMMUNOTHERAPY
- Peripheral Neuropathy Associated With Ipilimumab
- (2015) Iyavut Thaipisuttikul et al. JOURNAL OF IMMUNOTHERAPY
- Administration of Ipilimumab to a Liver Transplant Recipient With Unresectable Metastatic Melanoma
- (2015) Harsha A. Ranganath et al. JOURNAL OF IMMUNOTHERAPY
- Morphomics predicts response to ipilimumab in patients with stage IV melanoma
- (2015) Michael S. Sabel et al. JOURNAL OF SURGICAL ONCOLOGY
- Development of chronic lymphocytic leukaemia during ipilimumab therapy in a patient with metastatic melanoma
- (2015) M. Arenbergerova et al. JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY
- Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial
- (2015) Georgina V Long et al. LANCET
- Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial
- (2015) Alexander M M Eggermont et al. LANCET ONCOLOGY
- Severe Acute Orthopnea: Ipilimumab-Induced Bilateral Phrenic Nerve Neuropathy
- (2015) Praveen Jinnur et al. LUNG
- Improved Overall Survival in Melanoma with Combined Dabrafenib and Trametinib
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
- (2015) Michael A. Postow et al. NEW ENGLAND JOURNAL OF MEDICINE
- Pembrolizumab versus Ipilimumab in Advanced Melanoma
- (2015) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
- (2015) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- The Evolving Role of Immune Checkpoint Inhibitors in Cancer Treatment
- (2015) G. K. Pennock et al. ONCOLOGIST
- A Case Report of Orbital Inflammatory Syndrome Secondary to Ipilimumab
- (2015) Amanda D. Henderson et al. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
- Osteonecrosis of the jaw a new complication related to Ipilimumab
- (2015) Adepitan A. Owosho et al. ORAL ONCOLOGY
- Bilateral Facial Palsy following Ipilimumab Infusion for Melanoma
- (2015) Ashley L. Altman et al. OTOLARYNGOLOGY-HEAD AND NECK SURGERY
- Ipilimumab for Previously Untreated Unresectable Malignant Melanoma: A Critique of the Evidence
- (2015) Christina Giannopoulou et al. PHARMACOECONOMICS
- Immunotherapy and hypophysitis: clinical presentation, treatment, and biologic insights
- (2015) Alexander Faje Pituitary
- Phase II DeCOG-Study of Ipilimumab in Pretreated and Treatment-Naïve Patients with Metastatic Uveal Melanoma
- (2015) Lisa Zimmer et al. PLoS One
- Drug-Associated Dermatomyositis Following Ipilimumab Therapy
- (2015) Shirwa Sheik Ali et al. JAMA Dermatology
- Bilateral Choroidopathy and Serous Retinal Detachments During Ipilimumab Treatment for Cutaneous Melanoma
- (2015) Dimosthenis Mantopoulos et al. JAMA Ophthalmology
- Unusual pulmonary toxicity of ipilimumab treated by macrolides
- (2015) M. Mailleux et al. ACTA CLINICA BELGICA
- Ipilimumab-Induced Encephalopathy with a Reversible Splenial Lesion
- (2015) R. M. Conry et al. Cancer Immunology Research
- Impact of NRAS Mutations for Patients with Advanced Melanoma Treated with Immune Therapies
- (2015) D. B. Johnson et al. Cancer Immunology Research
- Febrile Neutropenia in a Metastatic Melanoma Patient Treated with Ipilimumab - Case Report
- (2015) Sebastian Woźniak et al. Oncology Research and Treatment
- Ipilimumab-Associated Retinopathy
- (2015) Jonathan Crews et al. Ophthalmic Surgery Lasers & Imaging Retina
- A systematic evaluation of abscopal responses following radiotherapy in patients with metastatic melanoma treated with ipilimumab
- (2015) Ravi A Chandra et al. OncoImmunology
- Ipilimumab was safe and effective in two patients with metastatic melanoma and end-stage renal disease
- (2015) Ludimila Cavalcante et al. Cancer Management and Research
- Ipilmumab and cranial radiation in metastatic melanoma patients: a case series and review
- (2015) Jonathan D. Schoenfeld et al. Journal for ImmunoTherapy of Cancer
- Safety and efficacy of ipilimumab to treat advanced melanoma in the setting of liver transplantation
- (2015) Rita E Morales et al. Journal for ImmunoTherapy of Cancer
- Baseline circulating IL-17 predicts toxicity while TGF-β1 and IL-10 are prognostic of relapse in ipilimumab neoadjuvant therapy of melanoma
- (2015) Ahmad A. Tarhini et al. Journal for ImmunoTherapy of Cancer
- Apical ballooning and cardiomyopathy in a melanoma patient treated with ipilimumab: a case of takotsubo-like syndrome
- (2015) Benjamin P Geisler et al. Journal for ImmunoTherapy of Cancer
- Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?
- (2015) Joanna Mangana et al. PLoS One
- Three-year follow-up of advanced melanoma patients who received ipilimumab plus fotemustine in the Italian Network for Tumor Biotherapy (NIBIT)-M1 phase II study
- (2014) A. M. Di Giacomo et al. ANNALS OF ONCOLOGY
- Early Administration of Infliximab for Severe Ipilimumab-Related Diarrhea in a Critically Ill Patient
- (2014) Steven P. Merrill et al. ANNALS OF PHARMACOTHERAPY
- First report of ipilimumab-induced Grover disease
- (2014) J. Munoz et al. BRITISH JOURNAL OF DERMATOLOGY
- Autoimmune Inflammatory Myopathy after Treatment with Ipilimumab
- (2014) Gary Hunter et al. CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES
- Outcomes of patients with metastatic melanoma treated with immunotherapy prior to or after BRAF inhibitors
- (2014) Allison Ackerman et al. CANCER
- Immunological and biological changes during ipilimumab treatment and their potential correlation with clinical response and survival in patients with advanced melanoma
- (2014) Ester Simeone et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Sequential Treatment with Ipilimumab and BRAF Inhibitors in Patients With Metastatic Melanoma: Data From the Italian Cohort of the Ipilimumab Expanded Access Program
- (2014) Paolo Antonio Ascierto et al. CANCER INVESTIGATION
- Ipilimumab treatment associated pituitary hypophysitis: Clinical presentation and imaging diagnosis
- (2014) Yosef Chodakiewitz et al. CLINICAL NEUROLOGY AND NEUROSURGERY
- Ipilimumab-induced colitis: a rare but serious side effect
- (2014) Alisha Hinds et al. ENDOSCOPY
- Predictive value of early 18F-FDG PET/CT studies for treatment response evaluation to ipilimumab in metastatic melanoma: preliminary results of an ongoing study
- (2014) Christos Sachpekidis et al. EUROPEAN JOURNAL OF NUCLEAR MEDICINE AND MOLECULAR IMAGING
- Combinations of Radiation Therapy and Immunotherapy for Melanoma: A Review of Clinical Outcomes
- (2014) Christopher A. Barker et al. INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS
- Kidney injuries related to ipilimumab
- (2014) Hassane Izzedine et al. INVESTIGATIONAL NEW DRUGS
- Ipilimumab Plus Sargramostim vs Ipilimumab Alone for Treatment of Metastatic Melanoma
- (2014) F. Stephen Hodi et al. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION
- Ipilimumab-Induced Hypophysitis: A Detailed Longitudinal Analysis in a Large Cohort of Patients With Metastatic Melanoma
- (2014) Alexander T. Faje et al. JOURNAL OF CLINICAL ENDOCRINOLOGY & METABOLISM
- Successful Administration of Ipilimumab to Two Kidney Transplantation Patients With Metastatic Melanoma
- (2014) Evan J. Lipson et al. JOURNAL OF CLINICAL ONCOLOGY
- Efficacy and safety of ipilimumab in elderly patients with pretreated advanced melanoma treated at Italian centres through the expanded access programme
- (2014) Vanna Chiarion Sileni et al. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH
- Combination Therapy with Anti–CTLA-4 and Anti–PD-1 Leads to Distinct Immunologic Changes In Vivo
- (2014) Rituparna Das et al. JOURNAL OF IMMUNOLOGY
- Ipilimumab-induced Autoimmune Pancytopenia in a Case of Metastatic Melanoma
- (2014) Pauline du Rusquec et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab-associated Sweet syndrome in a patient with high-risk melanoma
- (2014) Rachel L. Kyllo et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Ipilimumab-associated Sweet syndrome in a melanoma patient
- (2014) Rachel Gormley et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma
- (2014) Edward J Gettings et al. Multiple Sclerosis Journal
- Atypical neurological complications of ipilimumab therapy in patients with metastatic melanoma
- (2014) B. Liao et al. NEURO-ONCOLOGY
- Genetic Basis for Clinical Response to CTLA-4 Blockade in Melanoma
- (2014) Alexandra Snyder et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined BRAF and MEK Inhibition versus BRAF Inhibition Alone in Melanoma
- (2014) Georgina V. Long et al. NEW ENGLAND JOURNAL OF MEDICINE
- Combined Vemurafenib and Cobimetinib in BRAF-Mutated Melanoma
- (2014) James Larkin et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab-Induced Orbital Inflammation Resembling Graves Disease With Subsequent Development of Systemic Hyperthyroidism From CTLA-4 Receptor Suppression
- (2014) Gary E. Borodic et al. OPHTHALMIC PLASTIC AND RECONSTRUCTIVE SURGERY
- Pretreatment Serum VEGF Is Associated with Clinical Response and Overall Survival in Advanced Melanoma Patients Treated with Ipilimumab
- (2014) J. Yuan et al. Cancer Immunology Research
- Bevacizumab plus Ipilimumab in Patients with Metastatic Melanoma
- (2014) F. S. Hodi et al. Cancer Immunology Research
- Late-Onset Paraplegia after Complete Response to Two Cycles of Ipilimumab for Metastatic Melanoma
- (2014) Grainne M. O'Kane et al. Oncology Research and Treatment
- Late development of splenic sarcoidosis-like lesions in a patient with metastatic melanoma and long-lasting clinical response to ipilimumab
- (2014) Rikke Andersen et al. OncoImmunology
- Abscopal effects of radiotherapy on advanced melanoma patients who progressed after ipilimumab immunotherapy
- (2014) Antonio M Grimaldi et al. OncoImmunology
- Ipilimumab administration for advanced melanoma in patients with pre-existing Hepatitis B or C infection: a multicenter, retrospective case series
- (2014) Sowmya Ravi et al. Journal for ImmunoTherapy of Cancer
- Ipilimumab in pretreated metastastic uveal melanoma patients. Results of the Dutch Working group on Immunotherapy of Oncology (WIN-O)
- (2013) Sander Kelderman et al. ACTA ONCOLOGICA
- Ipilimumab-Associated Colitis: CT Findings
- (2013) Kyung Won Kim et al. AMERICAN JOURNAL OF ROENTGENOLOGY
- Myosite orbitaire associée à un traitement par ipilimumab
- (2013) M. Lecouflet et al. ANNALES DE DERMATOLOGIE ET DE VENEREOLOGIE
- Efficacy and safety of ipilimumab in patients with pre-treated, uveal melanoma
- (2013) M. Maio et al. ANNALS OF ONCOLOGY
- Efficacy and safety of ipilimumab in metastatic melanoma patients surviving more than 2 years following treatment in a phase III trial (MDX010-20)
- (2013) D. McDermott et al. ANNALS OF ONCOLOGY
- Q-TWiST analysis comparing ipilimumab/dacarbazine vs placebo/dacarbazine for patients with stage III/IV melanoma
- (2013) B Sherrill et al. BRITISH JOURNAL OF CANCER
- Clinical activity of ipilimumab for metastatic uveal melanoma
- (2013) Jason J. Luke et al. CANCER
- Patterns of onset and resolution of immune-related adverse events of special interest with ipilimumab
- (2013) Jeffrey S. Weber et al. CANCER
- Long-term survival and immunological parameters in metastatic melanoma patients who responded to ipilimumab 10 mg/kg within an expanded access programme
- (2013) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Efficacy and Safety of Retreatment with Ipilimumab in Patients with Pretreated Advanced Melanoma Who Progressed after Initially Achieving Disease Control
- (2013) C. Robert et al. CLINICAL CANCER RESEARCH
- Detection of Early Onset of Hypophysitis by 18F-FDG PET-CT in a Patient With Advanced Stage Melanoma Treated With Ipilimumab
- (2013) Bernies van der Hiel et al. CLINICAL NUCLEAR MEDICINE
- Melanoma-Associated Retinopathy Treated with Ipilimumab Therapy
- (2013) A. Audemard et al. DERMATOLOGY
- Sarcoidosis complicating anti-cytotoxic T-lymphocyte-associated antigen-4 monoclonal antibody biotherapy
- (2013) C. Tissot et al. EUROPEAN RESPIRATORY JOURNAL
- Severe acute respiratory distress syndrome due to ipilimumab
- (2013) Daniel Franzen et al. EUROPEAN RESPIRATORY JOURNAL
- Hypophysitis Caused by Ipilimumab in Cancer Patients: Hormone Replacement or Immunosuppressive Therapy
- (2013) A. Lammert et al. EXPERIMENTAL AND CLINICAL ENDOCRINOLOGY & DIABETES
- Ipilimumab-induced Perforating Colitis
- (2013) Kisha A. Mitchell et al. JOURNAL OF CLINICAL GASTROENTEROLOGY
- Ipilimumab Administration in Patients With Advanced Melanoma and Hepatitis B and C
- (2013) Anupa Sharma et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-Induced Hepatitis C Viral Suppression
- (2013) Steven Minter et al. JOURNAL OF CLINICAL ONCOLOGY
- Cutaneous and pulmonary sarcoidosis-like reaction associated with ipilimumab
- (2013) Ross B. Reule et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Cutaneous melanoma
- (2013) Alexander MM Eggermont et al. LANCET
- Association Between Ipilimumab and Celiac Disease
- (2013) Nicole M. Gentile et al. MAYO CLINIC PROCEEDINGS
- Ipilimumab-induced acute severe colitis treated by infliximab
- (2013) Cecile Pagès et al. MELANOMA RESEARCH
- Sweet’s syndrome in a patient with metastatic melanoma after ipilimumab therapy
- (2013) Sofya Pintova et al. MELANOMA RESEARCH
- Multifocal radiculoneuropathy during ipilimumab treatment of melanoma
- (2013) Georgios Manousakis et al. MUSCLE & NERVE
- Hepatotoxicity with Combination of Vemurafenib and Ipilimumab
- (2013) Antoni Ribas et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab for Patients With Advanced Mucosal Melanoma
- (2013) M. A. Postow et al. ONCOLOGIST
- Ipilimumab and Its Toxicities: A Multidisciplinary Approach
- (2013) L. A. Fecher et al. ONCOLOGIST
- The Price of Tumor Control: An Analysis of Rare Side Effects of Anti-CTLA-4 Therapy in Metastatic Melanoma from the Ipilimumab Network
- (2013) Caroline J. Voskens et al. PLoS One
- Drug-Associated Polymyalgia Rheumatica/Giant Cell Arteritis Occurring in Two Patients After Treatment With Ipilimumab, an Antagonist of CTLA-4
- (2013) Barbara L. Goldstein et al. Arthritis & Rheumatology
- Anti-PD1 Following Ipilimumab for Mucosal Melanoma: Durable Tumor Response Associated with Severe Hypothyroidism and Rhabdomyolysis
- (2013) L. Min et al. Cancer Immunology Research
- Ipilimumab and radiation therapy for melanoma brain metastases
- (2013) Ann W. Silk et al. Cancer Medicine
- Ipilimumab-induced autoimmune adrenalitis
- (2013) Le Min et al. Lancet Diabetes & Endocrinology
- Assessment of association between BRAF-V600E mutation status in melanomas and clinical response to ipilimumab
- (2012) Vafa Shahabi et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Ipilimumab in melanoma
- (2012) Pol Specenier Expert Review of Anticancer Therapy
- Health related quality of life outcomes for unresectable stage III or IV melanoma patients receiving ipilimumab treatment
- (2012) Dennis A Revicki et al. Health and Quality of Life Outcomes
- Severe meningo-radiculo-nevritis associated with ipilimumab
- (2012) Flavie Bompaire et al. INVESTIGATIONAL NEW DRUGS
- Pulmonary Sarcoid-Like Granulomatosis Induced by Ipilimumab
- (2012) Grégoire Berthod et al. JOURNAL OF CLINICAL ONCOLOGY
- A Severe Case of Ipilimumab-Induced Guillain-Barré Syndrome Revealed by an Occlusive Enteric Neuropathy
- (2012) Caroline Gaudy-Marqueste et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab in patients with melanoma and brain metastases: an open-label, phase 2 trial
- (2012) Kim Margolin et al. LANCET ONCOLOGY
- Elevated rates of transaminitis during ipilimumab therapy for metastatic melanoma
- (2012) Sebastian G. Bernardo et al. MELANOMA RESEARCH
- Ipilimumab in 2nd line treatment of patients with advanced melanoma: a cost-effectiveness analysis
- (2012) Victor Barzey et al. JOURNAL OF MEDICAL ECONOMICS
- Anti-CTLA-4 antibody-induced Guillain-Barre syndrome in a melanoma patient
- (2011) S. Wilgenhof et al. ANNALS OF ONCOLOGY
- Ipilimumab in pretreated patients with metastatic uveal melanoma: safety and clinical efficacy
- (2011) Riccardo Danielli et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Resolution of Severe Ipilimumab-Induced Hepatitis After Antithymocyte Globulin Therapy
- (2011) Katarzyna D. Chmiel et al. JOURNAL OF CLINICAL ONCOLOGY
- Posterior Reversible Encephalopathy Syndrome During Ipilimumab Therapy for Malignant Melanoma
- (2011) Michela Maur et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab-Induced Sarcoidosis in a Patient With Metastatic Melanoma Undergoing Complete Remission
- (2011) Wouter V. Vogel et al. JOURNAL OF CLINICAL ONCOLOGY
- Ipilimumab in Treatment-naive and Previously Treated Patients with Metastatic Melanoma
- (2011) John A. Thompson et al. JOURNAL OF IMMUNOTHERAPY
- Recent trends in cutaneous melanoma incidence and death rates in the United States, 1992-2006
- (2011) Ahmedin Jemal et al. JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
- Immunotherapies in Clinical Trials: Do They Demand Different Evaluation Tools?
- (2011) R. S. Tuma JNCI-Journal of the National Cancer Institute
- A prospective phase II trial exploring the association between tumor microenvironment biomarkers and clinical activity of ipilimumab in advanced melanoma
- (2011) Omid Hamid et al. Journal of Translational Medicine
- P034. Single-institution experience in an extended access program with the CTLA-4 blocking monoclonal antibody ipilimumab in pretreated melanoma patients
- (2011) D. Vander Stichele et al. MELANOMA RESEARCH
- Hemophilia A Induced by Ipilimumab
- (2011) Julie Delyon et al. NEW ENGLAND JOURNAL OF MEDICINE
- Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma
- (2011) Caroline Robert et al. NEW ENGLAND JOURNAL OF MEDICINE
- Efficacy and safety of ipilimumab monotherapy in patients with pretreated advanced melanoma: a multicenter single-arm phase II study
- (2010) S. J. O'Day et al. ANNALS OF ONCOLOGY
- Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting
- (2010) Geoffrey Y. Ku et al. CANCER
- Ipilimumab experience in heavily pretreated patients with melanoma in an expanded access program at the University Hospital of Siena (Italy)
- (2010) Anna Maria Di Giacomo et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- A phase II multicenter study of ipilimumab with or without dacarbazine in chemotherapy-naïve patients with advanced melanoma
- (2010) Evan M. Hersh et al. INVESTIGATIONAL NEW DRUGS
- Continuous systemic corticosteroids do not affect the ongoing regression of metastatic melanoma for more than two years following ipilimumab therapy
- (2010) Kaan Harmankaya et al. MEDICAL ONCOLOGY
- Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
- (2010) F. Stephen Hodi et al. NEW ENGLAND JOURNAL OF MEDICINE
- Infliximab in the Treatment of Anti-CTLA4 Antibody (Ipilimumab) Induced Immune-Related Colitis
- (2009) David R. Minor et al. CANCER BIOTHERAPY AND RADIOPHARMACEUTICALS
- A Randomized, Double-Blind, Placebo-Controlled, Phase II Study Comparing the Tolerability and Efficacy of Ipilimumab Administered with or without Prophylactic Budesonide in Patients with Unresectable Stage III or IV Melanoma
- (2009) J. Weber et al. CLINICAL CANCER RESEARCH
- Guidelines for the Evaluation of Immune Therapy Activity in Solid Tumors: Immune-Related Response Criteria
- (2009) J. D. Wolchok et al. CLINICAL CANCER RESEARCH
- Refractory Colitis Following Anti-CTLA4 Antibody Therapy: Analysis of Mucosal FOXP3+ T Cells
- (2009) James D. Lord et al. DIGESTIVE DISEASES AND SCIENCES
- Current systemic therapy for metastatic melanoma
- (2009) Sanjiv S Agarwala Expert Review of Anticancer Therapy
- Neutropenia in a Patient Treated With Ipilimumab (anti–CTLA-4 Antibody)
- (2009) Mojtaba Akhtari et al. JOURNAL OF IMMUNOTHERAPY
- Inflammatory Enteric Neuropathy With Severe Constipation After Ipilimumab Treatment for Melanoma
- (2009) Shailender Bhatia et al. JOURNAL OF IMMUNOTHERAPY
- Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study
- (2009) Jedd D Wolchok et al. LANCET ONCOLOGY
- Anti-CTLA4 Antibody–Induced Lupus Nephritis
- (2009) Fouad Fadel et al. NEW ENGLAND JOURNAL OF MEDICINE
- Immune-mediated red cell aplasia after anti-CTLA-4 immunotherapy for metastatic melanoma
- (2008) Ilyssa O. Gordon et al. CANCER IMMUNOLOGY IMMUNOTHERAPY
- Anti-CTLA4 Monoclonal Antibody Induced Sarcoidosis in a Metastatic Melanoma Patient
- (2008) A. Eckert et al. DERMATOLOGY
- Phase I/II Study of Ipilimumab for Patients With Metastatic Melanoma
- (2008) Jeffrey S. Weber et al. JOURNAL OF CLINICAL ONCOLOGY
- CTLA-4 blockade enhances polyfunctional NY-ESO-1 specific T cell responses in metastatic melanoma patients with clinical benefit
- (2008) J. Yuan et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- CTLA-4 blockade with ipilimumab induces significant clinical benefit in a female with melanoma metastases to the CNS
- (2008) F Stephen Hodi et al. Nature clinical practice. Oncology
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationCreate your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create Now